May 15, 2026
Argenica Therapeutics (ASX:AGN) establishes clinical advisory panel to support Phase 2b stroke trial
Argenica Therapeutics has assembled an internationally recognised stroke advisory panel as it prepares the Phase 2b clinical development pathway for ARG-007 in acute ischaemic stroke.